A. Rada

Combined Oral 5-Azacytidine and Romidepsin are Highly Effective in Patients with PTCL: A Multicenter Phase 2 Study.

G. Bhagat, Craig R Soderquist, C. Deng, 2020, Blood.

ORAL 5-AZACYTIDINE AND ROMIDEPSIN EXHIBIT MARKED ACTIVITY IN PATIENTS WITH PTCL: A MULTICENTER PHASE I STUDY.

G. Bhagat, Craig R Soderquist, C. Deng, 2019, Blood.

A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.

L. Schwartz, S. Cremers, C. Deng, 2018, Blood.

A Phase 1/2 Study of Oral 5-Azacitidine and Romidepsin in Patients with Lymphoid Malignancies Reveals Promising Activity in Heavily Pretreated Peripheral T-Cell Lymphoma (PTCL)

C. Deng, O. O’Connor, L. Falchi, 2017 .